Nanovector approach for co-delivery of Alectinib and Hesperidin via inhalational for lung cancer treatment: development, characterization, and preclinical studies.

待确认 10 由 lin du 发布于 2026/6/16 21:22:27

DOI:10.1080/17425247.2025.2487585
作者：Saeem Ahmad,?Shahnaj Bano,?Nasr A Emad,?Shadab Alam,?Anjali Rathee,?Iqra Zai,?Jayamanti Pandit,?Mohd Aqil,?Yasmin Sultana
文献类型：期刊论文
补充材料：只需要正文

Taylor & Francis

Abstract：Background: The current study aims to fabricate Nanostructured Lipid Carriers for the co-delivery of Alectinib and Hesperidin (ALB-HSD NLC) for non-small cell lung Cancer (NSCLC) via an inha

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

1天前

yduan

47c47bbe698711f1b9b934735aa3bc31.pdf

1天前

Book学术机器人

2026/6/16 21:22:27 未找到该文献，机器人已退出，请等待人工下载

2026/6/16 21:22:27 Book学术AI机器人收到请求，开始寻找文献

2026/6/16 21:22:27 已向机器人发送请求

1天前

lin du 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库The global clinical trial landscape for glaucoma over the past three decades: current status and future prospects